

Technology Advisory Committee B Interests Register

ID3822 Burosumab for treating X-linked hypophosphataemia in adults

Publication Date: Tbc.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Oliver Gardener-	Patient Expert	Direct – non-financial	<p>Feb 22 to Jan 23, XLH UK received 95% of its income from Kyowa Kirin</p> <p>Feb 22 to Jan 23, IXLHA received a restricted grant Kyowa Kirin, 71% of its income.</p> <p>Feb 23 to Jan 23, IXLHA received, £515 from Kyowa Kirin Australia as unrestricted donation.</p>	15/02/2024	N/A	It was agreed that Oliver's declaration would not prevent him from providing expert advice to the committee.
Margarita Vidal	Patient Expert	Direct – non-Financial	<p>Feb 22 to Jan 23, XLH UK received 95% of its income from Kyowa Kirin</p> <p>Feb 22 to Jan 23, IXLHA received a restricted grant Kyowa Kirin, 71% of its income.</p> <p>Feb 23 to Jan 23, IXLHA received, £515 from Kyowa Kirin Australia as unrestricted donation.</p>	15/02/2024	NA	It was agreed that Margarita's declaration would not prevent her from providing expert advice to the committee.

Kassim Javaid	Clinical Expert	Direct – non-financial	<p>Feb 22 to Jan 23, XLH UK received 95% of its income from Kyowa Kirin</p> <p>Feb 22 to Jan 23, IXLHA received a restricted grant Kyowa Kirin, 71% of its income.</p> <p>Feb 23 to Jan 23, IXLHA received, £515 from Kyowa Kirin Australia as unrestricted donation.</p>	15/02/2024	N/A	It was agreed that Kassim's declaration would not prevent him from providing expert advice to the committee.
Richard Keen	Clinical Expert	Direct – financial	Consultancy work for Kyowa Kirin in the field of XLH and its treatment Honorary from Kyowa Kirin for lectures on XLH	15/02/2024	N/A	It was agreed that Richard's declaration would not prevent him from providing expert advice to the committee.
Richard Keen	Clinical Expert	Direct – non-financial	Managing patients treated with Burosumab through an Early Access Programme funded by Kyowa Kirin Medical advisor and advocate for XLH-UK a patient charity.	15/02/2024	N/A	It was agreed that Richard's declaration would not prevent him from providing expert advice to the committee.

Dr Prithwiraj Das	TAC C Member	Non-Financial Professional	Prithwirjas works in life sciences, including pharmaceutical market access, as Founding Director of G2PR Ltd. He has not worked on these products/indications in the last 12+ months.	15/02/2024	N/A	It was agreed that Prithwiraj's declaration would not prevent him from being on the committee.
-------------------	-----------------	-------------------------------	---	------------	-----	--